GlassScriptPhysician profile
Amy Shah
NPI 1659733202
$6,848.00
in general payments reported to CMS, 2019-2025
39 companies · $2,534 in 2025
The $2,534 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $868 · 2023: $1,525 · 2024: $1,796 · 2025: $2,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,854.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $914.41 | 2022-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $825.22 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $705.54 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $582.31 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $396.04 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $292.72 | 2022-2025 | Korlym |
| Dexcom, INC. | $275.10 | 2022-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $269.90 | 2022-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $266.81 | 2024-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $258.20 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $256.55 | 2022-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.38 | 2019-2025 | Jardiance |
| Abbott Laboratories | $178.57 | 2023-2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $147.59 | 2024-2025 | |
| Madrigal Pharmaceuticals | $139.76 | 2025 | Rezdiffra |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $118.29 | 2022-2024 | Tymlos |
| Abbvie INC. | $113.45 | 2022-2025 | Synthroid |
| Amphastar Pharmaceuticals, INC. | $107.91 | 2024-2025 | |
| Horizon Therapeutics Plc | $69.20 | 2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $66.25 | 2024-2025 | |
| Kyowa Kirin, INC. | $61.84 | 2023-2025 | Crysvita |
| Ascensia Diabetes Care US INC. | $59.65 | 2024 | |
| Sandoz INC. | $56.53 | 2025 | Jubbonti |
| Amryt Pharma Holdings LTD | $49.43 | 2022 | |
| Recordati_rare_diseases_inc. | $43.08 | 2023-2024 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $40.95 | 2022-2024 | Farxiga |
| Ultragenyx Pharmaceutical INC. | $40.75 | 2022-2023 | |
| Tandem Diabetes Care, INC. | $33.75 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $30.68 | 2023 | |
| Ionis Pharmaceuticals, INC. | $30.57 | 2025 | Tryngolza |
| Merck Sharp & Dohme LLC | $27.26 | 2023 | Steglatro, Januvia |
| Averitas Pharma INC. | $24.38 | 2025 | Qutenza |
| Nevro Corp. | $23.18 | 2022 | |
| Antares Pharma, INC. | $23.08 | 2022 | |
| Sequel Med Tech, LLC | $22.33 | 2025 | Twiist |
| Grt US Holding, INC. | $20.95 | 2022 | |
| Echosens North America, INC. | $15.34 | 2023 | Fibroscan |
| Tersera Therapeutics LLC | $15.04 | 2023 | Xermelo |
| Cequr Corporation | $11.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.